Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
Go back to Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics| CAL-BAY INTL (NASDAQ: CBAY) | Delayed: 32.48 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $32.48 | 52 Week High | $3.04 | |||
| Open | $5.00 | 52 Week Low | $0.82 | |||
| Day High | $32.48 | P/E | N/A | |||
| Day Low | $32.48 | EPS | $0.00 | |||
| Volume | 30,140 | |||||
| Gilead Sciences (NASDAQ: GILD) | Delayed: 151.00 -0.22 (0.15%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $151.22 | 52 Week High | $108.63 | |||
| Open | $149.23 | 52 Week Low | $71.39 | |||
| Day High | $151.19 | P/E | 83.43 | |||
| Day Low | $149.23 | EPS | $1.81 | |||
| Volume | 6,181,391 | |||||
